Cost-effectiveness of Antenatal Rescreening among Pregnant Women for Hepatitis C in the United States

Antoine Chaillon; Adriane Wynn; Tatyana Kushner; Nancy Reau; Natasha K. Martin

doi:10.1093/cid/ciaa362

Cost-effectiveness of Antenatal Rescreening among Pregnant Women for Hepatitis C in the United States

Antoine Chaillon, Adriane Wynn, Tatyana Kushner, Nancy Reau, Natasha K. Martin

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

Original language	English
Pages (from-to)	E3355-E3357
Journal	Clinical Infectious Diseases
Volume	73
Issue number	9
DOIs	https://doi.org/10.1093/cid/ciaa362
State	Published - 1 Nov 2021

Keywords

economic
hepatitis C virus
pregnancy
testing
treatment

Access to Document

10.1093/cid/ciaa362

Cite this

@article{9d888e59475b434f991c5398bc7b1c4b,

title = "Cost-effectiveness of Antenatal Rescreening among Pregnant Women for Hepatitis C in the United States",

abstract = "To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.",

keywords = "economic, hepatitis C virus, pregnancy, testing, treatment",

author = "Antoine Chaillon and Adriane Wynn and Tatyana Kushner and Nancy Reau and Martin, {Natasha K.}",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].",

year = "2021",

month = nov,

day = "1",

doi = "10.1093/cid/ciaa362",

language = "English",

volume = "73",

pages = "E3355--E3357",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Cost-effectiveness of Antenatal Rescreening among Pregnant Women for Hepatitis C in the United States

AU - Chaillon, Antoine

AU - Wynn, Adriane

AU - Kushner, Tatyana

AU - Reau, Nancy

AU - Martin, Natasha K.

N1 - Publisher Copyright: © 2020 The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].

PY - 2021/11/1

Y1 - 2021/11/1

N2 - To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

AB - To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

KW - economic

KW - hepatitis C virus

KW - pregnancy

KW - testing

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85120420059&partnerID=8YFLogxK

U2 - 10.1093/cid/ciaa362

DO - 10.1093/cid/ciaa362

M3 - Article

C2 - 32282879

AN - SCOPUS:85120420059

SN - 1058-4838

VL - 73

SP - E3355-E3357

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Cost-effectiveness of Antenatal Rescreening among Pregnant Women for Hepatitis C in the United States

Abstract

Keywords

Access to Document

Fingerprint

Cite this